

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and  
Waiver under 21 U.S.C. §355 (n)(4)

Andrew C. Leon, Ph.D.

**Committee:** Psychopharmacologic Drugs Advisory Committee

**Meeting Date:** March 23, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to New Drug Application (NDA) 20-717/S-019, Provigil (modafinil tablets), sponsored by Cephalon, Inc., for the proposed indication for the treatment of attention deficit hyperactivity disorder (ADHD), I am eligible to receive a waiver under 21 U.S.C. §355(n)(4).

<b>Type of Interest</b>	<b>Nature</b>	<b>Magnitude</b>
Stock	Competitor	Valued from \$5,001 to \$25,000

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

\_\_\_\_\_/s/  
Signature of SGE

\_\_\_\_\_  
2/27/06  
Date